Medical Research Funding at Baylor Still Strong

Wednesday, June 16, 2010 09:30 AM

The Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute, received grants totaling nearly $35 million in 2009, despite an economy that's seen a marked decrease in charitable giving and government grants.

As part of the Baylor Health Care System in North Texas, BIIR is dedicated to the study of the human immune system. BIIR conducts advanced patient-oriented research focused on using the immune system to fight serious illnesses such as cancer, infectious diseases, and autoimmune conditions.

The multiple grants will benefit a variety of research programs at BIIR, including the following 

  --  Biodefense against infectious disease: The National Institutes of Health (NIH) has awarded a series of grants, totaling $27.5 million. These include a renewed grant, three supplementary grants funded by the American Recovery and Reinvestment Act and a five-year grant to support collaborations between BIIR scientists and researchers from within the US and several international centers.

  --  Vaccines for HIV, HPV and Hepatitis C: INSERM, the research organization of the French government, awarded $6.8 million to Baylor Research Institute from ANRS (the French AIDS agency) to develop and test HIV vaccines and additional funding for a hepatitis C program. BIIR also received a federal stimulus package grant from the NIH to study a treatment for HPV.

  --  Autoimmune Diseases: A five-year, $3.5 million award was granted from the NIH to establish an Autoimmunity Center of Excellence at BIIR, designed to support both clinical research as well as clinical trials. BIIR also received a renewal grant totaling $1.3 million for five years to study systemic juvenile arthritis. BIIR's Center for Personalized Medicine received a pilot project grant that will be used to develop genomic tools to help researchers diagnose and treat multiple sclerosis.

  --  Additional grants were received to further research in dendritic cell-based cancer vaccines and for continued research towards immunology in pregnant women.

“These awards are due to the extraordinary efforts of our physicians, scientists, researchers and staff," says Jacques Banchereau, PhD, director of BIIR.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs